Bluebird suspends gene therapy trials after two sickle cell patients develop cancer
Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the BB305 lentiviral vector is linked to AML and MDS cases.
The AML case involves a patient who was received LentiGlobin gene therapy for sickle cell disease in a phase 1/2 clinical trial more than five years ago. It is currently unclear whether the development of AML is linked to the BB305 lentiviral vector used in bluebird’s gene therapy.
Blu...
